<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650597</url>
  </required_header>
  <id_info>
    <org_study_id>CR100707</org_study_id>
    <secondary_id>42165279EDI1001</secondary_id>
    <secondary_id>2011-002861-39</secondary_id>
    <nct_id>NCT01650597</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      single ascending doses as well as repeated doses of JNJ-42165279 in healthy male
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-site, randomized (participants are assigned to treatment by chance),
      double-blind study (neither physician nor participant knows whether the participant is
      receiving active treatment or placebo). Placebo is an inactive substance that is compared
      with a drug to test whether the drug has a real effect. This study consists of two parts
      (part 1, single dosing and part 2, multiple dosing). Part 1: An alternating panel design will
      be used, whereby the first panel of 9 participants will receive the first, third, and fifth
      administered doses, while the second panel of 9 participants will receive the second, fourth,
      and sixth administered doses.Up to 2 additional dosings (1 per panel) may be evaluated to
      further understand the study drug. For each dose administration, 6 participants will be
      assigned to active treatment and 3 to placebo. Each participant will receive JNJ-42165279 on
      2 occasions and placebo once during the first 3 dosings. The planned doses of JNJ-42165279
      range from 2.5 to 500 mg. The sponsor and investigator will review blinded data associated
      with each dose prior to administration of the next dose. Participants will check into the
      study center the morning prior to each dosing (Day -1) and will remain at the center until
      discharge 72 hours after dosing (Day 4). Participants will be dosed approximately every 4
      weeks. Part 2: A separate cohort of 9 healthy male volunteers will receive repeated daily
      dosing of 100 mg JNJ-42165279 or placebo (6 participants will receive JNJ-42165279 and 3
      participants will receive placebo) for 6 consecutive days. Participants will check into the
      study center the morning prior to their first dosing (Day -1) and will remain at the center
      until discharge 72 hours after receiving their last dose on Day 6. Participants in Part 1 and
      2 will return for a follow-up visit 7 to 14 days after their final discharge from the study
      center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidents of adverse events amongst participants (Part 1)</measure>
    <time_frame>Day -21 to Day 114 (~19 wks)</time_frame>
    <description>As a measure of safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidents of adverse events amongst participants (Part 2)</measure>
    <time_frame>Day -21 to Day 23 (~6 wks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of JNJ-42165279 as measured by Cmax (Part 1)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Cmax is defined as maximum plasma concentration of JNJ-42165279.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of JNJ-42165279 as measured by Cmax (Part 2)</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of JNJ-42165279 as measured by AUC (Part 1)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>AUC is defined area under the plasma concentration time curve from 0 to t hours post dosing of JNJ-42165279.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of JNJ-42165279 as measured by AUC (Part 2)</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatty acid amide hydrolase (FAAH) inhibition in white blood cells (WBCs) (Part 1)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAAH inhibition in WBC (Part 2)</measure>
    <time_frame>Day 1 to Day 7 and Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on mood (Part 1)</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>This is measured by scores on Patient Reported Outcome (PRO) questionnaires (Profile of Mood States [POMS], State version of the State-Trait Anxiety Inventory [STAIS], and the Exercise-Induced Feeling Inventory [EFI]). The POMS is a valid and reliable self-report scale that can be utilized to assess both positive and negative, transient, fluctuating mood states. The STAIS is a commonly-used, validated instrument to assess anxiety. The EFI assesses emotions commonly associated with exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on mood (Part 2)</measure>
    <time_frame>Day 1 to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on cognition (Part 1)</measure>
    <time_frame>Day -1 and Day 1</time_frame>
    <description>This is assessed by the time to complete Trail Making Test (TMT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on cognition (Part 2)</measure>
    <time_frame>Day -1, Day 1 and Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on pain tolerance (Part 1)</measure>
    <time_frame>Day -1 to Day 2</time_frame>
    <description>This is measured by pressure pain tolerance threshold using an electronic pressure algometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on drowsiness (Part 2)</measure>
    <time_frame>Day 1 to Day 6</time_frame>
    <description>This is measured by Stanford Sleepiness Scale (SSS). This 7 point Likerttype scale is used to rate the drowsiness with the descriptors ranging from &quot;feeling active, vital, alert, and wide awake&quot; (score= 1) to &quot;no longer fighting sleep, sleep onset soon, and having dream like thoughts&quot; (score=7).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Part 1 - Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (parallel)- additional cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-42165279 2.5 - 500 mg oral</intervention_name>
    <description>Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.</description>
    <arm_group_label>Part 1 - Panel 1</arm_group_label>
    <arm_group_label>Part 1 - Panel 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.</description>
    <arm_group_label>Part 1 - Panel 1</arm_group_label>
    <arm_group_label>Part 1 - Panel 2</arm_group_label>
    <arm_group_label>Part 2 (parallel)- additional cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-42165279 100 mg oral</intervention_name>
    <description>Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.</description>
    <arm_group_label>Part 2 (parallel)- additional cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg.

          -  Must adhere to required contraception (subject and partner, if applicable) during the
             study and for 3 months after study

          -  Must agree to not donate sperm during the study and for 3 months after receiving the
             last dose of study drug

        Exclusion Criteria:

          -  Has history of or current clinically significant medical illness including cardiac
             arrhythmias or other cardiac disease, hematologic disease, coagulation disorders
             (including any abnormal bleeding or blood dyscrasias), lipid abnormalities,
             significant pulmonary disease, including bronchospastic respiratory disease, diabetes
             mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric
             disease, infection, recent surgery or trauma.

          -  Has history of malignancy within 5 years before screening (exceptions are squamous and
             basal cell carcinomas of the skin, or malignancy that in the opinion of the
             investigator, with concurrence with the sponsor's medical monitor, is considered cured
             with minimal risk of recurrence)

          -  Has clinically significant abnormal values for hematology, clinical chemistry,
             coagulation, or urinalysis at screening or at first admission to the study center.

          -  Has clinically significant abnormal physical examination, neurological examination,
             vital signs, or 12-lead electrocardiogram (ECG) at screening or at first admission to
             the study center. Subjects with a QTcF interval &gt;450 msec or QRS interval â‰¥110 msec
             will be excluded.

          -  Has use of any prescription or nonprescription medications or herbal supplements,
             except for paracetamol, within 14 days before the first dose of study drug.
             Paracetamol is not allowed within 1 day (Day -1) before the first dose of study drug.

          -  Has known allergy, hypersensitivity, or intolerance to hypromellose (the excipient of
             JNJ-42165279)

          -  Has Known allergy to heparin or history of heparin induced thrombocytopenia

          -  Has positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis
             B core antibody (HBcAB), hepatitis B surface antigen (HBsAg), or hepatitis C
             antibodies (HCV)

          -  Has history of significant drug or alcohol abuse within past 5 years, or has a
             positive drug screen

          -  Smoking or use of nicotine-containing substances within past 2 months

          -  Blood donation or blood loss within past 3 months

          -  Recent use of an investigational drug or device
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Principal Investigator</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Free fatty amides</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

